Obtaining manufacturing and marketing approval for Ad Spray (medical spray) and expanding into surgical applications
First written in FY2017-Q1. 6 of 7 entries say "Advanced", first in FY2018. Latest entry: FY2020-Q3.
No other company in this theme has enough history to compare yet.
- FY2020-Q3AdvancedAnnual report
「In addition to strong performance by the spray-type adhesion barrier AdSpray and the anesthetic analgesic fentanyl injection in the Hospital Systems Business, alliance business with pharmaceutical companies expanded. As a result, Hospital Company's revenue was ¥127.8 billion, up 1.5% year on year.」
AdSpray performed well following its launch and, together with fentanyl injections and alliance businesses with pharmaceutical companies, contributed to higher revenue at the Hospital Company. - FY2020-Q2AdvancedAnnual report
「In addition to strong performance by infusion pumps and syringe pumps in the Hospital Systems Business, the spray-type adhesion barrier AdSpray and the antipyretic analgesic Acelio, alliance business with pharmaceutical companies expanded. As a result, Hospital Company's revenue was ¥82.8 billion, up 2.0% year on year.」
AdSpray continued to perform well and, together with infusion pumps, syringe pumps, Acelio and the alliance business, contributed to higher revenue at the Hospital Company. - FY2019-Q3AdvancedAnnual report
「Sales were strong for infusion solutions, the spray-type adhesion barrier AdSpray and the antipyretic analgesic Acelio in the Hospital Systems business. In addition, the alliance business expanded its partnerships with pharmaceutical companies, resulting in a 4.7% year-on-year increase in the Hospital Company's revenue to ¥125.9 billion.」
AdSpray continued to perform well after its launch and, together with infusion products, Acelio and the alliance business, contributed to higher revenue at the Hospital Company. - FY2019-Q2AdvancedAnnual report
「The sprayable adhesion barrier AdSpray performed well.」
AdSpray continued to perform well after its launch and contributed to higher revenue at the Hospital Company. - FY2019-Q1AdvancedAnnual report
「The sprayable adhesion barrier AdSpray performed well.」
The disclosure stated that AdSpray performed well in the first quarter following the start of sales. - FY2018AdvancedAnnual report
「The Hospital Company began selling AdSpray, Japan's first sprayable adhesion barrier.」
AdSpray moved into the sales phase following the acquisition of manufacturing and marketing approval. - FY2017-Q1First statedAnnual report
「In June, manufacturing and marketing approval was obtained for AdSpray, Japan's first sprayable adhesion barrier for use in surgery.」
The disclosure described for the first time the launch of AdSpray as a specific new product following the acquisition of manufacturing and marketing approval in June.